ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2025
Evaluation of a real-time hospital surveillance system for respiratory syncytial virus, Ontario, Canada, 2022-2023.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) surged in the 2022-2023 respiratory season after low activity during the pandemic. To monitor the RSV season in real time and support healthcare planning, Ontario introduced daily hospital bed census reporting of RSV hospitalizations by age group (0-17, 18-64, 65 years and older). Objectives: To assess the completeness and quality of the newly introduced real-time surveillance compared to end-of-season ICD-10 coded hospitalization discharge abstract data (DAD) from November 22, 2022, to March 31, 2023. Methods: Respiratory syncytial virus hospitalizations from both data sources were compared to RSV laboratory positivity to assess concordance with overall RSV activity. A longitudinal comparison by age group was assessed by time-lagged cross-correlation of the daily submission data versus DAD data, including cross correlation coefficients for each time lag, confidence bound and the highest correlation value. Results: Both data sources followed trends in RSV positivity. Data by age groups showed an early peak of paediatric admissions followed by a peak in adult and older adult hospitalizations. Daily surveillance consistently underestimated hospitalizations with a peak of 430 beds by DAD on January 7, 2023, versus 322 beds (75%) for daily reporting on the same day. The maximum correlation coefficient values were 0.67 (all ages), 0.57 (0-17 years), 0.66 (18-64 years) and 0.63 (65 years and older). Conclusion: Implementation of daily hospital reporting provided accurate trending in RSV hospitalizations by age group to inform within season healthcare and public health planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.